Trenbol-H Trenbolone Hexahydrobenzylcarbonate 76.5 mg/ml

• Category: Long-acting injectable anabolic–androgenic steroid (AAS) – Research Only
• Brand: Royal Pharmaceuticals
• Concentration: 76.5 mg/ml trenbolone hexahydrobenzylcarbonate
• Packing: 10 1 ml ampoules
• Origin: United Kingdom
• Research Use: Laboratory, analytical and reference purposes only. Not for human or veterinary use.

What Is Trenbolone Hexahydrobenzylcarbonate?

Trenbolone hexahydrobenzylcarbonate (also known as Parabolan, Hexabolan) is a long-acting trenbolone ester of the 19-nor testosterone family.

It functions as a depot prodrug: after intramuscular injection, the bulky hexahydrobenzylcarbonate ester releases free trenbolone over an extended period.

Originally marketed in France as Parabolan (1980–1997), it no longer has any approved medical use. Today it appears exclusively as a research and analytical compound.

Mechanism of Action

1. Androgen Receptor Activation

Once released from the ester, trenbolone binds strongly to the androgen receptor (AR), producing:

• High anabolic signalling
• Enhanced nitrogen retention
• Increased protein synthesis
• Stimulation of erythropoiesis

2. Non-aromatising profile

Trenbolone does not aromatise to estradiol.

3. Progestogenic activity

Trenbolone analogues display measurable progestogenic effects, contributing to HPG-axis suppression and potential endocrine interactions.

4. Depot Kinetics

The hexahydrobenzylcarbonate ester gives a long release duration, with an effective half-life of ~8–11 days.

Research Applications

• Androgen receptor binding and signalling studies
• Comparative anabolic vs androgenic tissue-selectivity models
• Structure–activity analysis of trenbolone esters
• Reference material for LC-MS/MS / GC-MS steroid profiling
• Anti-doping method development for trenbolone metabolites
• Pharmacokinetic modelling of long-acting androgen esters

Potential Research-Level Observations

• Powerful anabolic response relative to dose
• Low water-retention profile compared with aromatising AAS
• Strong recomposition markers in pre-clinical models
• Distinct metabolite profile ideal for analytical method calibration

Note: These points reflect biochemical properties, not performance claims.

Safety Profile & Possible Risks

Androgenic / Virilisation

• Acne, seborrhoea, oily skin
• Accelerated androgenic alopecia
• Deepened voice, virilisation in females

Endocrine Suppression

• Marked LH/FSH suppression
• Reduced endogenous testosterone
• Testicular atrophy and reduced fertility

Cardiometabolic

• Severe HDL reduction, LDL elevation
• Possible increases in blood pressure
• Cardiac remodelling concerns from AAS literature

Neuropsychological

• Irritability, mood swings, anxiety
• Sleep disturbance
• Aggression reports in uncontrolled exposure

Injection-Related

Local irritation

“Tren cough” episodes if oil enters bloodstream

Toxicological Classification (SDS)

• Carcinogenic (H350 – may cause cancer)
• Reproductive toxicant (H360 – may damage fertility)
• Very toxic to aquatic life (H410)

Compliance & Regulatory Information

• Controlled substance in many regions (Schedule III in USA)
• WADA S1 – prohibited at all times
• No approved medical indication globally
• Laboratory handling requires PPE, controlled storage, hazard waste procedures
• Not a supplement, not OTC, not a therapeutic product

Technical Data Table

Intended Use

Analytical, laboratory and research applications only

Research chemical — not for human or veterinary administration.